The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO 2022 | Personalized medicine for patients with GISTs

Name: Personalized medicine for patients with GISTs
Uploaded: 2022-06-03T00:00:00Z
Duration: 2 min 8 s
Description: Michael C. Heinrich, MD, OHSU Knight Cancer Institute, Portland, OR, reflects on emerging biomarkers in predicting treatment responses in patients with gastrointestinal stromal tumors, highlighting the use of circulating tumor DNA (ctDNA) to personalize treatment approaches. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Michael C. Heinrich • 3 Jun 2022

ASCO 2022

Gastrointestinal Cancer Sarcoma

INTRIGUE

Michael C. Heinrich, MD, OHSU Knight Cancer Institute, Portland, OR, reflects on emerging biomarkers in predicting treatment responses in patients with gastrointestinal stromal tumors, highlighting the use of circulating tumor DNA (ctDNA) to personalize treatment approaches. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.